Although Rho/Rho kinase inhibitors have been used in a variety of cancer models to study tumor progression and/or metastasis [23, 29, 30], neither their effects on tumor angiogenesis and vascular normalization nor upstream regulators of this pathway have been identified. The gene discussed is RHO; the disease is neoplasm.